In this video, Motley Fool health care analyst Brenton Flynn highlights a couple of emerging trends that medical technology investors should be watching. The first thing he has his eye on is a new procedure called renal denervation, a method to treat patients with hypertension who don't respond to medication. His second area to watch is how different pharmaceutical and biotech companies push into emerging markets, and how they address the need for more value-oriented solutions in these areas.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/21/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.